Phio Pharmaceuticals presents data about INTASYL

Phio Pharmaceuticals announced it is presenting new data about INTASYL on March 21st. The event is scheduled to take place at the 10th Immunotherapy of Cancer Conference, which will be held in Munich, Germany from March 21-23, 2024. The poster, Enhancing NK cell cytotoxicity against tumor cells with a novel self-delivering RNAi compound targeting Cbl-b, reveals new preclinical data demonstrating the potential of treatment with INTASYL self-delivering siRNA Compound PH-905, formerly known as Compound 27547, to improve function of natural killer cells. The preclinical data demonstrate the following: INTASYL self-delivering RNAi compound PH-905 effectively targets and silences Cbl-b in primary NK cells without negative impact on their viability. Silencing of Cbl-b results in increased proliferation of primary NK cells. INTASYL silencing of Cbl-b in primary NK cells enhanced their functional cytotoxicity towards tumor cells. Silencing of Cbl-b leads to enhanced fitness of NK cells through increased expression of CD98 and CD25, potentially improving NK metabolism and promoting activation in response to IL-2. INTASYL compound PH-905 may be used to improve the anti-tumor response of NK cells to provide a more effective cell therapy for cancer treatment